Genetics and response to treatment with metformin for type 2 diabetes.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2025-10-01 DOI:10.1080/14622416.2025.2565992

Laurence Tessier, Sophie St-Amour, Dorianne Simard, Joanie Bouchard, Patrice Perron, Karine Tremblay

引用次数: 0

Abstract

Diabetes is a chronic disease that affects approximately 589 million people worldwide. Type 2 diabetes is one of its main forms (~90%) and manifests as hyperglycemia due to the resistance of myocytes and adipocytes to insulin. These are unable to capture and use blood glucose. In the long term, T2D can lead to a reduced production of insulin by beta cells, leading to more complex complications. Metformin is the first-line treatment for this condition. However, it may not always be effective for regulating blood glucose levels. Some factors, such as genetics, may influence the drug efficacy for this disease. The aim of this review is to summarize the pharmacogenetic variants associated with response to metformin in T2D treatment.

查看原文本刊更多论文

遗传学和二甲双胍治疗2型糖尿病的反应。

糖尿病是一种慢性疾病，影响着全世界约5.89亿人。2型糖尿病是其主要形式之一（约占90%），表现为由于肌细胞和脂肪细胞对胰岛素的抵抗而引起的高血糖。它们不能捕获和利用血糖。从长期来看，T2D可导致β细胞产生胰岛素减少，从而导致更复杂的并发症。二甲双胍是治疗此病的一线药物。然而，它可能并不总是有效地调节血糖水平。一些因素，如遗传，可能会影响这种疾病的药物疗效。本综述的目的是总结与二甲双胍治疗T2D反应相关的药物遗传变异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.